Quantcast

Industry news that matters to you.  Learn more

Immunogenicity Testing Proves Invaluable

Immunogenicity is a measure of the immune response to a biotherapeutic drug. It is a very relevant issue affecting not only the use of therapeutic protein drugs such as mAbs but also peptides, enzymes, cytokines, growth factors, recombinant proteins, and other biological products.

Circadian Granted Key Strategic VEGF-D Patent in USA for Diagnostic Applications

Circadian Technologies has reported that its subsidiary company, Vegenics Limited, has been granted US Patent 7785803 claiming diagnostic kits for the detection of VEGF-D in human samples such as blood.

VEGF-D, a major novel target for cancer and other diseases, has been shown to be a prognostic indicator of survival or disease progression in a number of different cancer types as well as a biomarker for various respiratory diseases.

TGen partner, PBS-Bio, makes first breakthrough drug analysis

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

Duke, LabCorp Launch ‘Factory’ to Translate Biomarkers into Personalized Medicine Tests

If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?

Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.